ISPC VS ABBV Stock Comparison
Performance
ISPC10/100
10/100
ISPC returned -65.85% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
ABBV100/100
100/100
ABBV returned -4.80% in the last 12 months. Based on SPY's performance of -20.59%, its performance is above average giving it a score of 100 of 100.
Sentiment
ISPC61/100
61/100
ISPC had a bullish sentiment score of 61.25% across Twitter and StockTwits over the last 12 months. It had an average of 1.00 posts, 0.00 comments, and 0.00 likes per day.
ABBV71/100
71/100
ABBV had a bullish sentiment score of 71.15% across Twitter and StockTwits over the last 12 months. It had an average of 130.21 posts, 1,504.50 comments, and 7,664.76 likes per day.
Technicals
ISPC21/100
21/100
ISPC receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.
ABBV11/100
11/100
ABBV receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
ISPC10/100
10/100
ISPC has missed earnings 7 times in the last 20 quarters.
ABBV100/100
100/100
ABBV has missed earnings 0 times in the last 20 quarters.
Profit
ISPC10/100
10/100
Out of the last 17 quarters, ISPC has had 0 profitable quarters and has increased their profits year over year on 0 of them.
ABBV80/100
80/100
Out of the last 20 quarters, ABBV has had 18 profitable quarters and has increased their profits year over year on 11 of them.
Volatility
ISPC53/100
53/100
ISPC has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
ABBV47/100
47/100
ABBV has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
Analyst Price Targets
ISPC
"Analyst Price Targets" not found for ISPC
ABBV68/100
68/100
20 analysts offer 12-month price targets for ABBV. Together, they have an average target of 158.73, the most optimistic target put ABBV at 200 within 12-months and the most pessimistic has ABBV at 127.
Dividend
ISPC
"Dividend" not found for ISPC
ABBV100/100
100/100
ABBV's most recent dividend was $0.97 per share, based on a share price of $138.93. It was a payout ratio of 53.19% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
iSpecimen Inc. Common Stock Summary
Nasdaq / ISPC
Healthcare
Medical - Diagnostics & Research
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
ABBVIE INC. Summary
New York Stock Exchange / ABBV
Healthcare
Drug Manufacturers - General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ISPC to other companies in the same or a similar industry.